View Article

Abstract

The main aim of the present study is to formulate and evaluate ezetimibe nanoemulsion to enhance its solubility, stability, and therapeutic efficacy. Ezetimibe, a poorly water-soluble antihyperlipidemic drug, exhibits limited bioavailability, making it a suitable candidate for nanoemulsion-based delivery. Oils, surfactants, and co-surfactants were screened through solubility studies, leading to the selection of Capryol 90, Tween 80, and Transcutol HP as optimal components. Pseudo-ternary phase diagrams were constructed to identify suitable nanoemulsion regions, and formulations were prepared using aqueous titration followed by homogenization. The developed formulations were evaluated for thermodynamic stability, droplet size, polydispersity index (PDI), zeta potential, viscosity, pH, drug content, and in vitro diffusion. Among the tested formulations, F2 demonstrated superior characteristics with a droplet size of 97 nm, a zeta potential of –28.3 mV, and drug content of 95.92 ± 0.62%. In vitro diffusion studies confirmed a rapid and sustained drug release profile, achieving 96.5% cumulative release within 60 minutes. FTIR analysis confirmed drug–excipient compatibility without evidence of chemical degradation. The findings suggest that ezetimibe nanoemulsion represents a promising drug delivery system to overcome solubility limitations and improve therapeutic performance.

Keywords

Solubility enhancement, Ezetimibe, Drug delivery, Stability

Introduction

Nanoemulsions are thermodynamically stable colloidal dispersions formed by mixing two immiscible liquids with the aid of surfactants and co-surfactants, which lower interfacial tension and yield a uniform phase. They are usually transparent or translucent and are also described as ultrafine, submicron, or mini-emulsions. Depending on the arrangement of dispersed and continuous phases, nanoemulsions are categorized as oil-in-water (O/W), where oil droplets are distributed in water; water-in-oil (W/O), where water droplets are distributed within oil; and bi-continuous systems, in which microdomains of both oil and water coexist throughout the formulation.[1]

COMPONENTS OF NANOEMULSION

Table 1: Lists of components

Components

Examples

Oil

Capryol 90, Castor oil, Labrafil

Surfactant

Labrasol, Tween 40, Tween 80

Co-Surfactant

Transcutol HP, PEG 400, Polysorbate 80

Aqueous phase

Distilled water

METHODS OF PREPARATION

There are many techniques used to create nanoemulsion drug delivery systems, and many of them overlap. We have grouped these methods based on how much energy they require, the type of phase inversion involved, and whether they use self-emulsification. High energy methods include high-pressure homogenization, microfluidization, and ultrasonication. Low energy methods include phase inversion emulsification, which can be transitional (such as phase inversion temperature or composition) or catastrophic (such as emulsion inversion point), as well as the self-nanoemulsification method.[2]

  1. High energy methods
  1. High-Pressure Homogenization

This technique involves the application of high pressure to a system containing an oil phase, an aqueous phase & a surfactant or co-surfactant. The pressure is exerted using specialized equipment known as a homogenizer. However, there are several issues associated with homogenizers, including low productivity, component degradation due to challenges in mass production, and excessive heat generation. This method is limited to producing only oil-in-water (o/w) liquid nanoemulsions with an oil phase of less than 20%, and it is not capable of creating cream nanoemulsions with high viscosity or hardness that have a mean droplet diameter of less than 200nm.[3]

  1. Microfluidization

Microfluidization is a technique for mixing that employs a device known as a microfluidizer. This device operates using a high-pressure positive displacement pump, which can range from 500 to 20,000psi, to propel the product through an interaction chamber composed of small channels referred to as 'microchannels'. As the product traverses these microchannels, it reaches an impingement area, leading to the formation of extremely fine particles within the sub-micron range. The two phases, namely the aqueous & oily phases, are amalgamated & processed in an inline homogenizer to create a coarse emulsion. Subsequently, this coarse emulsion is introduced into a microfluidizer for further processing, aiming to achieve a stable nanoemulsion. The coarse emulsion is cycled through the interaction chamber of the microfluidizer multiple times until the target particle size is reached. Finally, the bulk emulsion is filtered through a filter under nitrogen to eliminate larger droplets, resulting in a consistent nanoemulsion.[4]

  1. Ultrasonication

Sonication, also known as ultrasonic homogenization, is employed to produce kinetically stable nanoemulsions. In this process, a sonicator probe is placed in contact with a dispersion containing liquids, surfactants, and cosurfactants. The probe generates mechanical vibrations and cavitation, supplying the energy required to form small droplets. Sonication is commonly utilized for small-scale nanoemulsion production. To avoid shear-induced coalescence, operational parameters must be carefully controlled. The particle size of the dispersed phase decreases as the duration of sonication, power input, and surfactant concentration increase. Achieving a droplet size of approximately 20 nm requires optimization of the ultrasonic reaction chamber design, operating conditions, and formulation variables such as surfactant concentration and oil phase composition. A primary limitation of sonication is its unsuitability for preparing large volumes of nanoemulsions.[5]

  1. Low energy methods

For the preparation of nanoemulsion systems, these methods require low energy.
Low-energy emulsification techniques are more energy efficient as they use internal chemical energy of the systems & only require gentle stirring for the creation of nanoemulsions.[2]

  1. Phase inversion temperature

In the phase inversion temperature (PIT) method, the temperature of the emulsion system is raised to alter the solubilizing behavior of the surfactant (from hydrophilic to lipophilic), resulting in the formation of bicontinuous microemulsions and subsequent emulsion inversion. This process consists of four steps:

(i) When the temperature is below the PIT, a macro-emulsion is present, characterized by nonionic surfactants, primarily hydrophilic.

(ii) As the temperature increases, the surfactants slowly transition to a lipophilic state and become solubilized by the oil phase.

(iii) At the PIT, bicontinuous microemulsions are formed.

(iv) When the temperature exceeds the PIT, the emulsion undergoes inversion, with water being dispersed into the mixture of oil and lipophilic surfactant. The system is then rapidly cooled through water dilution, which instantaneously renders the surfactant hydrophilic, thereby prompting spontaneous and swift migration to the aqueous phase. This turbulent displacement facilitates the generation of nanoemulsions.[6]

  1. Emulsion Inversion point (EIP)

The EIP method represents a low-energy & spontaneous approach to emulsification. Under constant temperature conditions, this method facilitates the alteration of the intrinsic characteristics of thermodynamically stable microemulsions or liquid crystals, transforming them into nano-structured forms through a gradual dilution with either water or oil. This process leads to the formation of thermodynamically unstable yet kinetically stable direct or inverse nanoemulsions. A minor adjustment in the ratio of water or oil within the established microemulsion system will modify the surfactant hydration pattern & its affinity for the aqueous phase. Consequently, this induces instabilities within the microemulsion system, ultimately resulting in its disintegration into nano-emulsion.[6]

  1. Spontaneous Emulsification Method

Spontaneous emulsions are generated in this method by combining water & oil with an emulsifier through gentle stirring at a specific temperature. The gentle magnetic stirring facilitates the mixing of phases, allowing the emulsifier to migrate into the aqueous phase, which increases the oil-water interfacial area & leads to the formation of oil droplets. Spontaneous emulsification consists of three primary steps, which are as follows:

  • The creation of a homogeneous organic solution that includes oil & a lipophilic surfactant in a water-miscible solvent, along with a hydrophilic surfactant.
  • The organic phase is then injected into the aqueous phase while magnetic stirring is applied, resulting in the formation of the oil-in-water emulsion.
  • Finally, the water-miscible solvent is eliminated through evaporation under reduced pressure.[7]

Applications of Nanoemulsions

The nanoemulsions are used in a wide range of fields like pharmaceuticals, biomedical fields, cosmetics, food, agriculture, and industry because of their unique physicochemical properties and ability to improve solubility, stability, and targeted delivery of active compounds.

Pharmaceutical Applications

In pharmaceutical industry, the nanoemulsions are used in various drug delivery systems as they can increase the solubility of poorly water soluble drugs, thus increasing their bioavailability and therapeutic efficacy. Nanoemulsions facilitate the controlled and targeted release of active ingredients, thereby decreasing the frequency of doses and minimizing side effects. Furthermore, they provide safeguarding for delicate compounds from enzymatic or oxidative breakdown, thereby guaranteeing stability throughout formulation and storage. Owing to their small droplet size and extensive surface area, nanoemulsions can be efficiently delivered via various routes including oral, parenteral, transdermal, ocular, and pulmonary, positioning them as a promising platform for contemporary pharmaceutical applications.

Cosmetic Applications

Nanoemulsion is extensively utilized in the cosmetic sector because its active components are readily absorbed, resulting in effective action due to its characteristic properties, including a small droplet size and the capacity to minimize water loss from the skin. Nanoemulsions are employed in moisturizers, lotions, and creams. As an appealing delivery system in cosmetics, the droplet size of nanoemulsions is extremely small, preventing creaming and flocculation, which contributes to a more refined product that enhances uptake by antigen-presenting cells in stable formulations. The incorporation of nanoemulsion in cosmetic products facilitates the swift penetration of active ingredients through the skin, attributed to the large surface area of the droplets. It is also observed that nanoemulsions can penetrate effectively through rough skin. This characteristic of nanoemulsion reduces the need for additional penetration enhancers, which can lead to formulation incompatibility.[8]

Nanoemulsion in Food industry

Nanoemulsions present a diverse array of applications owing to their compositional versatility across various sectors, particularly in the food and beverage industries. In contrast to microemulsions, nanoemulsions have gained significant traction in food processing due to their diminutive size, thermodynamic stability, and the ability to continuously self-assemble with both hydrophilic and hydrophobic components. Their transparency and minimal light wave scattering capabilities ultimately facilitate their integration into optically clear products, such as enhanced soft drinks and bottled waters. Unlike traditional micro or other standard emulsions, nanoemulsions can be formulated to exhibit greater viscosity or a gel-like consistency, even at very low droplet concentrations, making them suitable for creating products with reduced fat content and innovative textures.[9]

Advantages and Disadvantages of Nanoemulsions

ADVANTAGES

  • Increased solubility of drugs that are poorly-water soluble.
  • Bioavailability enhancement.
  • Reduce dose frequency.
  • Improve patient compliance.
  • It has rapid onset of action.

DISADVANTAGES

  • It requires high surfactant concentrations which leads to the risk of irritation or toxicity.
  • The nanoemulsion stability is affected by the environmental factors like pH, temperature etc.
  • High production costs.
  • Thermodynamically unstable.

MATERIALS AND METHODS

MATERIALS

Table 2: Equipment’s List

S. No.

Equipment

Make/Model

1.

Weighing Balance

Essae

2.

UV-Visible spectrophotometer

Shimadzu UV-1800

3.

Cyclomixer

Remi CM 101

4.

Zeta sizer

Malvern-Nano ZS90

5.

Centrifuge

REMI equipment pvt limited

6.

Micropipette

PFfact

7.

Magnetic Stirrer

REMI 1MLH

8.

FTIR

Bruker Company

9.

Homogenizer

Remi RQ 121

Table 3: Lists of Chemicals

S. No.

Chemicals

Category

Manufacturer

1.

Ezetimibe

Drug

Aurobindo

2.

Capryol 90

Oil

Gatte Fosse Pvt. Ltd. Mumbai

3.

Labrafil M 1944 CS

Oil

Gatte Fosse Pvt. Ltd. Mumbai

4.

Labrafac PG

Oil

Gatte Fosse Pvt. Ltd. Mumbai

5.

Labrafac Lipophile WL 1349

Oil

Gatte Fosse Pvt. Ltd. Mumbai

6.

Capmul MCM C8 EP

Oil

ABITEC Corporation

7.

Capmul PG8 NF

Oil

ABITEC Corporation

8.

Capmul MCM NF

Oil

ABITEC Corporation

9.

Oleic acid

Oil

Reasearch-Lab Fine Chem Industries

10.

Peceol

Oil

Gatte Fosse Pvt. Ltd. Mumbai

11.

Tween 40

Surfactant

Fluka

12.

Tween 80

Surfactant

Fluka

13.

Labrasol ALF

Surfactant

Gatte Fosse Pvt. Ltd. Mumbai

14.

Lauroglycol FCC

Surfactant

Gatte Fosse Pvt. Ltd. Mumbai

15.

Kolliphor RH 40

Surfactant

Gatte Fosse Pvt. Ltd. Mumbai

16.

Transcutol HP

Co-Surfactant

Gatte Fosse Pvt. Ltd. Mumbai

17.

Propylene glycol

Co-Surfactant

Sisco SO Fine chem Limited

18.

PEG 400

Co-Surfactant

SDFCL SO Fine chem Limited

19.

PEG 600

Co-Surfactant

SDFCL SO Fine chem Limited

20.

Plurol oleique

Co-Surfactant

Gatte Fosse Pvt. Ltd. Mumbai

21.

Acetonitrile

Analytical agent

Avra Synthesis Pvt.Ltd.

METHODOLOGY

Standard calibration curve of Ezetimibe in Acetonitrile

  • Determination of λmax using UV spectrophotometer

The λmax of drug sample was determined by scanning 10ppm standard stock solution in the range from 200-400nm using Shimadzu-1800 UV spectrometer.

  • Construction of calibration curve by UV spectroscopy

Ezetimibe (10mg) was dissolved in Acetonitrile (10ml).[1000µg/ml] 1ml was taken from the above solution and made upto 10ml with acetonitrile. [100µg/ml] Dilutions were made 5ppm, 10ppm, 15ppm, 20ppm, 25ppm and were subjected to UV spectrophotometer. Absorbance was measured at 231nm.

SOLUBILITY STUDIES

Solubility of Ezetimibe in various components (oils, surfactants & cosurfactants) was determined by adding an excess amount of drug in 500mg of selected vehicle in 5ml capacity stoppered vials, and mixed using a cyclomixer. These vials were then kept at 25±10C in an shaking incubator for 72h to reach equilibrium. The balanced samples were taken out of the shaker and subjected to centrifugation at 3000rpm for a duration of 15 minutes. The supernatant was collected & the concentration of drug was determined using UV spectrophotometer.

FTIR (Fourier Transform Infrared Spectroscopy)

FTIR analysis was performed to evaluate potential interactions between the pure drug (Ezetimibe) & the excipients in the optimized nanoemulsion formulation. A small quantity of each sample (pure drug and nanoemulsion formulation) was taken and dissolved in a minimal amount of chloroform in a clean china dish using a mortar and pestle to aid dispersion. Using a capillary tube, a thin film of the solution was carefully applied onto clean, dry potassium bromide (KBr) or sodium chloride (NaCl) discs and allowed to form a uniform layer. The discs were subsequently positioned within the sample holder of the FTIR spectrophotometer for measurement. The spectra were in the range of 4000 to 400cm-1. A background spectrum was collected prior to each sample scan. The recorded spectra were analyzed for the presence, shift, or disappearance of characteristic peaks, indicating potential interactions or encapsulation of the drug within the formulation matrix.

Construction of pseudo ternary phase diagrams

  • According to solubility studies, capryol 90 was chosen as the oil phase for the development of the nanoemulsion.
  • Tween 80 and Transcutol HP served as the surfactant and co surfactant, respectively. Distilled water constituted the aqueous phase.
  • The surfactant and cosurfactant were mixed (Smix) in volume ratios of 4:1, 3:1, 1:3, 2:1, and 1:1. For each phase diagram, the oil and Smix ratios were thoroughly mixed in various volume ratios ranging from 1:9 to 9:1.
  • Phase diagrams were constructed utilizing the aqueous titration method.
  • The physical state of the nanoemulsion was indicated on a pseudo three component phase diagram, with one axis denoting the aqueous phase, another representing the oil, and the third illustrating the mixture of surfactant and cosurfactant at a fixed volume ratios (Smix), using TernaryPlot.com.

FORMULATION OF NANOEMULSION

Prepare the homogeneous mixture of oil and Smix (surfactant & cosurfactant). Ezetimibe was precisely measured and subsequently incorporated into the aforementioned mixture. Oil phase then added drop wise to the aqueous phase with continuous mixing using homogenizer leads to the formation of O/W nanoemulsion.

Optimized formulae of Nanoemulsions

Table 4: Optimized formulae of Nanoemulsions

Formulation code

Drug(mg)

Oil: S mix ratio

S mix ratio

Oil

(%v/v)

Surfactant

(%v/v)

Cosurfactant

(%v/v)

Water

(%v/v)

F1

120

3:7

4:1

16.06

26.26

7.09

50.60

F2

120

3:7

3:1

15.97

24.48

8.80

50.75

F3

120

1:9

3:1

5.41

31.94

11.50

51.15

F4

120

5:5

2:1

12.5

8.33

4.17

75

F5

120

1:9

1:3

5.32

10.48

33.93

50.27

F6

120

4:6

1:1

10

7.5

7.5

75

EVALUATION OF NANOEMULSION FORMULATIONS

THERMODYNAMIC STABILITY STUDIES

Selected formulations underwent a series of thermodynamic stability assessments to evaluate their physical stability.

Centrifugation

The prepared formulations were centrifuged at 5000rpm for 30min & observed for phase separation, creaming or cracking.

Freeze Thaw Cycle

A required quantity of the nanoemulsion was transferred into a vial & subjected to three freeze–thaw cycles by storing it at −25?°C for one hour followed by room temperature for one hour. Three freeze-thaw cycles between -21°C & +25°C with formulation storage at each temperature for not less than 48 h were performed.

Determination of particle size and polydispersity index (PDI)

The particle size & PDI of nanoemulsions are evaluated using photon correlation spectroscopy (PCS) with the Malvern Zetasizer, which observes the changes in light scattering due to the Brownian motion of particles over time. PCS operates on the principle that smaller particles move at a higher velocity compared to larger particles. To measure particle size, a specific amount of the formulation is dispersed in distilled water to create a homogeneous dispersion, which must be utilized immediately for the measurement of particle size and PDI.

Determination of zeta potential

The zeta potential serves as a technique for assessing the surface charge of particles when immersed in a liquid medium. This measurement is instrumental in forecasting the stability of dispersions, with its value being influenced by the physicochemical characteristics of the drug, polymer, vehicle, and the presence and adsorption of electrolytes. The Malvern Zetasizer instrument is utilized for this measurement. To determine the zeta potential, the nanoemulsion is diluted & its value is derived from the electrophoretic mobility of the oil droplets. A zeta potential of ±30mV is considered adequate for maintaining the physical stability of the nanoemulsion.

Drug content

A 1mL aliquot of the nanoemulsion formulation was transferred into a 10mL volumetric flask & diluted to volume with acetonitrile. The resulting solution was analyzed for drug content using a UV-visible spectrophotometer at a wavelength of 231nm.

pH

The measured apparent pH of the formulations was determined using a pH meterin triplicate at a temperature of 25°C.

Viscosity

The viscosity of the formulated nanoemulsions was measured undiluted using a Brookfield Viscometer with spindle #C50-1 at a temperature of 25±0.5?C. 1ml of the formulation was utilized for the purpose of determining viscosity. The speed of the spindle was adjusted to 50rpm & a single run was performed at a temperature of 25±0.5?C.

In vitro diffusion studies

A study on in vitro diffusion was performed using a Franz diffusion cell. The investigation was performed using an eggshell membrane. The membrane was prepared appropriately and preserved in a pH 7.4 phosphate buffer prior to its application. A phosphate buffer solution with a pH of 7.4 served as the diffusion medium, and the receptor compartment was filled with this solution. The membrane of the eggshell was placed between the donor & recipient sections of the diffusion cell. One milliliter of the test formulation was added to the donor compartment. The temperature of the diffusion medium was regulated at 37±1°C, while the buffer solution was continuously agitated with a magnetic bead at a rate of 500 to 700 rpm. Samples were extracted from the release medium at intervals of 5, 10, 15, 30, 45, 60, 90, 120, 180, and 240 minutes & replaced with an equivalent volume of fresh buffer solution to sustain sink conditions. The samples were analyzed spectrophotometrically at a wavelength of 231 nm against their corresponding blank.

Stability studies

Stability evaluation of the optimized nanoemulsion was performed at accelerated storage conditions (40 °C/75% RH).

RESULTS AND DISCUSSION

Calibration plot of Ezetimibe

Determination of λmax

λmax of Ezetimibe in acetonitrile was found to be 231nm. When examined in the range of 200-400nm, Ezetimibe showed an absorption maxima at 231nm in acetonitrile. Different concentrations were prepared using acetonitrile. A correlation coefficient of R²=0.9941 was shown in the calibration data.

Fig1: Spectrum of Ezetimibe

Calibration curve of Ezetimibe

Table 5: Calibration Curve of Ezetimibe

Concentration (µg/ml)

Absorbance

(Mean±SD)

5

0.201±0.048

10

0.371±0.064

15

0.476±0.065

20

0.599±0.038

25

0.724±0.056

n=3

Fig2: Calibration Curve of Ezetimibe at λmax 231nm(n=3)

SOLUBILITY STUDIES OF EZETIMIBE

Table 6: Solubility of Ezetimibe in different oils

Oils

Solubility of ezetimibe (mg/ml)

Capryol 90

86.550 ± 0.91

Capmul MCM C8 EP

69.148 ± 3.41

Capmul MCM NF

53.815 ±  5.15

Capmul PG8 NF

77.545 ± 2.15

Peceol

17.203 ± 1.90

Oleic acid

69.160 ± 2.94

Labrafil M 1944 CS

67.486 ± 5.58

Labrafac PG

59.74 ± 1.28

Labrafac Lipophile WL 1349

52.768 ± 0.95

n = 3

Table 7: Solubility of Ezetimibe in different Surfactants & Co-Surfactants

Surfactants & Co-Surfactants

Solubility of ezetimibe (mg/ml)

Tween 80

94.54 ± 0.54

Tween 40

77.552 ± 4.46

Labrasol ALF

66.091 ± 1.67

Kolliphor RH 40

29.170 ± 4.54

Lauroglycol FCC

63.793 ± 2.49

Transcutol HP

83.910 ± 0.75

Propylene glycol

49.171 ± 3.76

PEG 400

73.846 ± 2.17

PEG 600

77.560 ± 2.98

Plurol oleique

12.824 ± 2.98

n = 3

Fig 3: Graph depicting solubility of Ezetimibe in different oils(n=3)

Fig 4: Graph depicting solubility of Ezetimibe in different surfactants & co-surfactants(n=3)

Drug Excipient compatibility studies

Using the FTIR spectrophotometer, the compatibility of pharmacological excipients was examined. FTIR data of the drug alone and the drug combined with the excipients suggested that there was no apparent interaction between the medication & the used excipients.

Table 8: Interpretation of pure drug (Ezetimibe) and optimized formulation (F2)

S. No

Wavenumber of Ezetimibe(cm?¹)

Wavenumber of optimized Formulation F2 (cm?¹)

Probable Functional Group / Vibration

Interpretation

1

3248

3416

O–H / N–H stretching

Broadening & shift indicate H-bonding or interaction

2

2910, 2850

2927

Aliphatic C–H stretching

Slight shift; possible interaction with surfactant/oil

3

1882

1842

Strained or conjugated C=O (possibly artifact)

Peak shift; could suggest conformational change or encapsulation

4

1510, 1594

Aromatic C=C stretching

Disappearance suggests drug is no longer free/crystalline

5

1104, 1060

1104

C–O stretching (ether or ester)

Partial retention; indicates structural compatibility

6

894

=C–H out-of-plane bending

Disappearance indicates possible encapsulation or loss of free drug

7

517, 431

517, 403

Fingerprint region (C–X, skeletal bending)

Retained; no major chemical changes

DISCUSSION: The FTIR spectra of pure Ezetimibe & its optimized nanoemulsion formulation were analyzed to investigate potential interactions. In the pure drug spectrum, characteristic peaks were observed at 3248cm?¹ (O–H/N–H), 2910 and 2850cm?¹ (C–H), 1882 cm?¹ (C=O), 1594 and 1510 cm?¹ (aromatic C=C), and peaks in the fingerprint region such as 1104, 1060, and 894 cm?¹. In the formulation, the O–H/N–H peak shifted to 3416 cm?¹ and became broader, indicating hydrogen bonding with excipients. The C–H peak shifted to 2927 cm?¹, and the carbonyl region showed a shift from 1882 cm?¹ to 1842 cm?¹. Notably, several aromatic and fingerprint peaks (1510, 894 cm?¹) disappeared, suggesting successful drug encapsulation and a reduction in crystallinity. Overall, the FTIR results confirm physical interactions without chemical degradation, supporting the stability and compatibility of the nanoemulsion system.

PSEUDO TERNARY PHASE DIAGRAM

Pseudo ternary phase diagram of Smix ratio 4:1

Table 9: Pseudo ternary phase diagram of Smix ratio 4:1

Blank formulation code

Oil

(mg)

Smix

(mg)

(4:1)

Water

(mg)

Total

(mg)

Oil%

Smix%

Water%

Remarks

CT4T1 (1:9)

50

450

2734

3234

1.54

13.91

84.53

Transparent

CT4T1 (2:8)

100

400

3048

3548

2.81

11.27

85.90

Transparent

CT4T1 (3:7)

150

350

3333

3833

3.91

9.13

86.95

Transparent with slight blue

CT4T1 (4:6)

200

300

2175

2675

7.47

11.21

81.30

Transparent

CT4T1 (5:5)

250

250

2255

2755

9.07

9.07

81.85

Transparent

CT4T1 (6:4)

300

200

2028

2528

11.86

7.91

80.22

Transparent

CT4T1 (7:3)

350

150

2294

2794

12.52

5.36

82.10

Transparent

CT4T1 (8:2)

400

100

3336

3836

10.42

2.606

86.96

Transparent

CT4T1 (9:1)

450

50

2224

2724

16.51

1.835

81.64

Transparent

Fig10: Different ratios of oil and Smix (4:1)

Pseudo ternary phase diagram of Smix ratio 3:1

Table 10: Pseudo ternary phase diagram of Smix ratio 3:1

Blank formulation code

Oil

(mg)

Smix

(mg)

(3:1)

Water

(mg)

Total

(mg)

Oil%

Smix%

Water%

Remarks

CT3T1 (1:9)

50

450

1338

1838

2.72

24.48

72.79

Translucent

CT3T1 (2:8)

100

400

1370

1870

5.34

21.39

73.26

Turbid

CT3T1 (3:7)

150

350

933

1433

10.46

24.42

65.10

Blue colour gel

CT3T1 (4:6)

200

300

598

1098

18.21

27.32

54.46

Milky white

CT3T1 (5:5)

250

250

402

902

27.71

27.716

44.56

Transparent

CT3T1 (6:4)

300

200

288

788

38.07

25.38

36.54

Phase separation

CT3T1 (7:3)

350

150

202

702

49.85

21.367

28.77

Phase separation

CT3T1 (8:2)

400

100

214

714

56.02

14.005

29.97

Phase separation

CT3T1 (9:1)

450

50

201

701

64.19

7.1326

28.67

Phase separation

Fig11: Different ratios of oil and Smix (3:1)

Pseudo ternary phase diagram of Smix ratio 2:1

Table 11: Pseudo ternary phase diagram of Smix ratio 2:1

Blank formulation code

Oil

(mg)

Smix

(mg)

(2:1)

Water

(mg)

Total

(mg)

Oil%

Smix%

Water%

Remarks

CT2T1 (1:9)

50

450

1394

1894

2.63

23.75

73.60

Translucent

CT2T1 (2:8)

100

400

1649

2149

4.65

18.61

76.73

Turbid

CT2T1(3:7)

150

350

1237

1737

8.63

20.14

71.21

Milky white

CT2T1(4:6)

200

300

807

1307

15.30

22.95

61.74

Turbid

CT2T1 (5:5)

250

250

319

819

30.52

30.52

38.94

Slight blue colour

CT2T1 (6:4)

300

200

306

806

37.22

24.81

37.96

Phase separation

CT2T1 (7:3)

350

150

200

700

50

21.42

28.57

Phase separation

CT2T1(8:2)

400

100

205

705

56.73

14.18

29.07

Phase separation

CT2T1 (9:1)

450

50

105

605

74.38

8.26

17.35

Phase separation

Fig12: Different ratios of oil and Smix (2:1)

Pseudo ternary phase diagram of Smix ratio 1:3

Table 12: Pseudo ternary phase diagram of Smix ratio 1:3

Blank formulation code

Oil

(mg)

Smix

(mg)

(2:1)

Water

(mg)

Total

(mg)

Oil%

Smix%

Water%

Remarks

CT1T3 (1:9)

50

450

1389

1889

2.64

23.82

73.53

Translucent

CT1T3 (2:8)

100

400

1788

2288

4.37

17.48

78.14

Turbid

CT1T3(3:7)

150

350

1344

1844

8.13

18.98

72.88

Turbid

CT1T3(4:6)

200

300

606

1106

18.08

27.12

54.79

Phase separation

CT1T3 (5:5)

250

250

542

1042

23.99

23.99

52.01

Phase separation

CT1T3 (6:4)

300

200

257

757

39.63

26.42

33.94

Phase separation

CT1T3 (7:3)

350

150

158

658

53.19

22.79

24.012

Phase separation

CT1T3(8:2)

400

100

104

604

66.22

16.55

17.21

Phase separation

CT1T3 (9:1)

450

50

158

658

68.38

7.59

24.01

Phase separation

Pseudo ternary phase diagram of Smix ratio 1:1

Table 13: Pseudo ternary phase diagram of Smix ratio 1:1

Blank formulation code

Oil

(mg)

Smix

(mg)

(2:1)

Water

(mg)

Total

(mg)

Oil%

Smix%

Water%

Remarks

CT1T1 (1:9)

50

450

510

1010

4.95

44.55

50.49

Translucent

CT1T1 (2:8)

100

400

729

1229

8.13

32.54

59.31

Translucent

CT1T1(3:7)

150

350

717

1217

12.32

28.75

58.91

Turbid

CT1T1(4:6)

200

300

306

806

24.81

37.22

37.96

Slight blue colour

CT1T1(5:5)

250

250

314

814

30.71

30.75

38.57

Phase separation

CT1T1(6:4)

300

200

203

703

42.67

28.44

28.87

Phase separation

CT1T1(7:3)

350

150

206

706

49.57

21.24

29.17

Phase separation

CT1T1(8:2)

400

100

101

601

66.55

16.63

16.80

Phase separation

CT1T1(9:1)

450

50

102

602

74.75

8.30

16.94

Phase separation

Fig14: Different ratios of oil and Smix (1:1)

EVALUATION OF NANOEMULSION

Table 14: Evaluation of optimized ezetimibe nanoemulsion formulations

Formulation

Drug Content

pH

Viscosity

Centrifugation

Freeze Thaw cycle

F1

68.5±0.30%

5.6 ± 0.1

43.2 ± 2.1

Pass

Pass

F2

95.92±0.62%

5.5 ± 0.1

39.5 ± 0.6

Pass

Pass

F3

89±0.42%

5.7 ± 0.1

33.1 ± 1.6

Pass

Pass

F4

55.33±0.55%

5.6 ± 0.1

35.4 ± 1.8

Fail

Fail

F5

88.21±0.22%

5.5 ± 0.1

40.2 ± 2.0

Pass

Pass

F6

54.28±0.16%

5.8 ± 0.1

30.6 ± 1.5

Fail

Fail

Table 15: Particle size, zeta potential and PDI of optimized aqueous titration solutions.

Code

Particle size

Zeta potential

PDI

CT4T1(3:7)

186.88nm

-13.2mV

0.443

CT4T1(8:2)

706.18nm

-4.2mV

0.253

CT3T1(3:7)

89nm

-24.2mV

0.365

CT3T1(1:9)

201.2nm

-20.1mV

0.433

CT1T3(1:9)

159nm

-14.9mV

0.339

Table 16: Particle size, zeta potential and PDI of optimized ezetimibe nanoemulsions formulations

Formulation Code

Particle size

Zeta potential

PDI

F1

209.45nm

-18.9mV

0.345

F2

97nm

-28.3mV

0.421

F3

260.6nm

-25.2mV

0.525

F5

178nm

-16.3mV

0.258

Diffusion Studies

Table 17: % cumulative drug release of optimized formulation F2

Time(min)

% CDR

5

25.8 ± 3.65

10

34.84 ± 2.80

15

42.7 ± 4.34

30

56.03 ± 2.58

45

73.6 ± 3.43

60

96.5 ± 3.01

Fig 20: Graph depicting the %CDR graphs of optimized formulation F2(n=3)

Stability Studies

Stability studies for the F2 formulation were carried out at 40 °C and 75% relative humidity.

Duration

Drug Content

pH

Viscosity

Centrifugation

Freeze Thaw cycle

In vitro diffusion studies

Initial

95.92±0.62%

5.5 ± 0.1

39.5 ± 0.6

Pass

Pass

96.5 ± 3.01

First month

94.37±0.40%

5.5 ± 0.1

39.5 ± 0.6

Pass

Pass

96.5 ± 3.01

Second month

92.96±0.52%

5.5 ± 0.1

39.8 ± 0.8

Pass

Pass

96.4 ± 2.65

Third month

91.54±0.32%

5.5 ± 0.1

39.8 ± 0.9

Pass

Pass

95.7 ± 2.04

CONCLUSION

Ezetimibe, an anti-hyperlipidemia which belongs to the BCS class II, is formulated as a nanoemulsion to enhance solubility and to control release of the drug in the body. The ezetimibe nanoemulsion is prepared by using capryol 90 as oil, tween 80 & transcutol HP as surfactant & co-surfactant, which are selected based upon the solubility studies conducted. The calibration curve was plotted by using acetonitrile, in which λmax was found to be 231nm, and the regression coefficient was 0.9941. The pseudoternary phase diagrams were designed to find out the composition of components to form the desired optimum nanoemulsion. By using pseudoternary phase diagrams, a total of 6 formulations were prepared, in which F2 was found to have a small particle size and was more stable than the other formulations. The drug-excipient compatibility studies were also directed for the optimized F2 formulation, which shows physical interactions without any chemical degradation, supporting the stability and compatibility of the nanoemulsion. All the nanoemulsion formulations were evaluated for particle size, PDI, zeta potential, pH, viscosity, centrifugation, freeze-thaw cycle, drug content & in vitro diffusion studies. From this study, I conclude that the ezetimibe nanoemulsion prepared using capryol 90, tween 80 & transcutol hp having Smix ratio of 3:1and oil to Smix ratio of 3:7 has shown particle size of 97nm & zeta potential of -28.3mV and it also shows the controlled release of drug which is optimum for the drug delivery as compared to the conventional dosage form.

REFERENCE

  1. Verma NK, Singh AK, Yadav V, Mall PC, Jaiswal R. International Journal of Pharmacy and Pharmaceutical Science, Volume 1; Issue 1; 2019; Page No. 30-38.
  2. Abdulelah FM, Taghi HS, Abdulbaqi HR, Abdulbaqi MR. Review on Nanoemulsion: Preparation and Evaluation. International Journal of Drug Delivery Technology. 2020; 10(1):187-189.
  3. Kumar M, Bishnoi RS, Shukla AK, Jain CP. Techniques for formulation of nanoemulsion drug delivery system: A review. Preventive nutrition and food science. 2019 Sep 30;24(3):225.
  4. Sharma N, Bansal M, Visht S, Sharma PK, Kulkarni GT. Nanoemulsion: A new concept of delivery system. Chronicles of Young Scientists. 2010 Apr 1;1(2):2-6.
  5. Amin N, Das B. A review on formulation and characterization of nanoemulsion. International Journal of Current Pharmaceutical Research. 2019 Jul 15;11(4):1-5.
  6. Jasmina H, Džana O, Alisa E, Edina V, Ognjenka R. Preparation of nanoemulsions by high-energy and lowenergy emulsification methods. InCMBEBIH 2017: Proceedings of the International Conference on Medical and Biological Engineering 2017 2017 Mar 15 (pp. 317-322). Singapore: Springer Singapore.
  7. Sutradhar KB, Amin ML. Nanoemulsions: increasing possibilities in drug delivery. European Journal of Nanomedicine. 2013 Jul 1;5(2):97-110.
  8. Malode MG, Chauhan SA, Bartare SA, Malode LM, Manwar JV, Bakal RL. A critical review on nanoemulsion: Advantages, techniques and characterization. Journal of Applied Pharmaceutical Sciences and Research. 2021;4(3):6-12.
  9. Chellapa P, Ariffin FD, Eid AM, Almahgoubi AA, Mohamed AT, Issa YS, Elmarzugi NA. Nanoemulsion for cosmetic application. European Journal of Biomedical and Pharmaceutical Sciences. 2016;3(7):8-11.
  10. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. Journal of Drug Delivery and Therapeutics. 2019 Mar 15;9(2):520-527.
  11. Gajjar, Anuradha & Shah, Vishal. (2011). Impurity Profiling: A Case Study of Ezetimibe. The Open Conference Proceedings Journal. 211. 108-112.
  12. Bali V, Ali M, Ali J. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids and Surfaces B: Biointerfaces. 2010 Apr 1;76(2):410-20.
  13. Priyanka Shukla et al, A Complete Review On Nanoemulsion., Indo Am. J. P. Sci, 2022; 09(01).
  14. Shaikh NM, Vijayendra Swamy SM, Nagoba SN, Kulkarni KB, Formulation and Evaluation of Nanoemulsion for Topical Application, Journal of Drug Delivery and Therapeutics. 2019; 9(4-s):370-375
  15. Sadeq ZA. Review on nanoemulsion: Preparation and evaluation. International Journal of Drug Delivery Technology. 2020;10(1):187-9.
  16. Gurpreet K, Singh SK. Review of nanoemulsion formulation and characterization techniques. Indian Journal of Pharmaceutical Sciences. 2018 Sep 1;80(5).
  17. Prasad D, Mohanta GP, Sudhakar M. A review on preparation and evaluation of nanoemulsions. Int J Pharm Res Health Sci. 2019;7(1):2915-22.
  18. Reddy MS, Tripura Sundari P. Formulation and evaluation of nanoemulsion for solubility enhancement of febuxostat. IJSDR1901020 International Journal of Scientific Development and Research. 2019 Jan;4(1).
  19. R Dabhi M, D Limbani M, R Sheth N. Preparation and in vivo evaluation of self-nanoemulsifying drug delivery system (SNEDDS) containing ezetimibe. Current Nanoscience. 2011 Aug 1;7(4):616-27.
  20. Amin N, Das B. A review on formulation and characterization of nanoemulsion. International Journal of Current Pharmaceutical Research. 2019 Jul 15;11(4):1-5.
  21. Maha HL, Sinaga KR, Masfria M. Formulation and evaluation of miconazole nitrate nanoemulsion and cream. Asian J Pharm Clin Res. 2018;11(3):319-21.
  22. Jain K, Bharkatiya M. Nanoparticulate based ocular drug delivery technology:“Nanoemulsion a novel approach”. Indian J Pharma Pharmacol. 2020;7(3):168-176.

Reference

  1. Verma NK, Singh AK, Yadav V, Mall PC, Jaiswal R. International Journal of Pharmacy and Pharmaceutical Science, Volume 1; Issue 1; 2019; Page No. 30-38.
  2. Abdulelah FM, Taghi HS, Abdulbaqi HR, Abdulbaqi MR. Review on Nanoemulsion: Preparation and Evaluation. International Journal of Drug Delivery Technology. 2020; 10(1):187-189.
  3. Kumar M, Bishnoi RS, Shukla AK, Jain CP. Techniques for formulation of nanoemulsion drug delivery system: A review. Preventive nutrition and food science. 2019 Sep 30;24(3):225.
  4. Sharma N, Bansal M, Visht S, Sharma PK, Kulkarni GT. Nanoemulsion: A new concept of delivery system. Chronicles of Young Scientists. 2010 Apr 1;1(2):2-6.
  5. Amin N, Das B. A review on formulation and characterization of nanoemulsion. International Journal of Current Pharmaceutical Research. 2019 Jul 15;11(4):1-5.
  6. Jasmina H, Džana O, Alisa E, Edina V, Ognjenka R. Preparation of nanoemulsions by high-energy and lowenergy emulsification methods. InCMBEBIH 2017: Proceedings of the International Conference on Medical and Biological Engineering 2017 2017 Mar 15 (pp. 317-322). Singapore: Springer Singapore.
  7. Sutradhar KB, Amin ML. Nanoemulsions: increasing possibilities in drug delivery. European Journal of Nanomedicine. 2013 Jul 1;5(2):97-110.
  8. Malode MG, Chauhan SA, Bartare SA, Malode LM, Manwar JV, Bakal RL. A critical review on nanoemulsion: Advantages, techniques and characterization. Journal of Applied Pharmaceutical Sciences and Research. 2021;4(3):6-12.
  9. Chellapa P, Ariffin FD, Eid AM, Almahgoubi AA, Mohamed AT, Issa YS, Elmarzugi NA. Nanoemulsion for cosmetic application. European Journal of Biomedical and Pharmaceutical Sciences. 2016;3(7):8-11.
  10. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. Journal of Drug Delivery and Therapeutics. 2019 Mar 15;9(2):520-527.
  11. Gajjar, Anuradha & Shah, Vishal. (2011). Impurity Profiling: A Case Study of Ezetimibe. The Open Conference Proceedings Journal. 211. 108-112.
  12. Bali V, Ali M, Ali J. Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Colloids and Surfaces B: Biointerfaces. 2010 Apr 1;76(2):410-20.
  13. Priyanka Shukla et al, A Complete Review On Nanoemulsion., Indo Am. J. P. Sci, 2022; 09(01).
  14. Shaikh NM, Vijayendra Swamy SM, Nagoba SN, Kulkarni KB, Formulation and Evaluation of Nanoemulsion for Topical Application, Journal of Drug Delivery and Therapeutics. 2019; 9(4-s):370-375
  15. Sadeq ZA. Review on nanoemulsion: Preparation and evaluation. International Journal of Drug Delivery Technology. 2020;10(1):187-9.
  16. Gurpreet K, Singh SK. Review of nanoemulsion formulation and characterization techniques. Indian Journal of Pharmaceutical Sciences. 2018 Sep 1;80(5).
  17. Prasad D, Mohanta GP, Sudhakar M. A review on preparation and evaluation of nanoemulsions. Int J Pharm Res Health Sci. 2019;7(1):2915-22.
  18. Reddy MS, Tripura Sundari P. Formulation and evaluation of nanoemulsion for solubility enhancement of febuxostat. IJSDR1901020 International Journal of Scientific Development and Research. 2019 Jan;4(1).
  19. R Dabhi M, D Limbani M, R Sheth N. Preparation and in vivo evaluation of self-nanoemulsifying drug delivery system (SNEDDS) containing ezetimibe. Current Nanoscience. 2011 Aug 1;7(4):616-27.
  20. Amin N, Das B. A review on formulation and characterization of nanoemulsion. International Journal of Current Pharmaceutical Research. 2019 Jul 15;11(4):1-5.
  21. Maha HL, Sinaga KR, Masfria M. Formulation and evaluation of miconazole nitrate nanoemulsion and cream. Asian J Pharm Clin Res. 2018;11(3):319-21.
  22. Jain K, Bharkatiya M. Nanoparticulate based ocular drug delivery technology:“Nanoemulsion a novel approach”. Indian J Pharma Pharmacol. 2020;7(3):168-176.

Photo
M. Swathi Ramani
Corresponding author

Department of Pharmaceutics, Centre for Pharmaceutical Sciences, UCESTH, Jawaharlal Nehru Technological University, Hyderabad, Kukatpally, Telangana-500085, India.

Photo
M. Sunitha Reddy
Co-author

Department of Pharmaceutics, Centre for Pharmaceutical Sciences, UCESTH, Jawaharlal Nehru Technological University, Hyderabad, Kukatpally, Telangana-500085, India.

Photo
K. Anie Vijetha
Co-author

Department of Pharmaceutics, Centre for Pharmaceutical Sciences, UCESTH, Jawaharlal Nehru Technological University, Hyderabad, Kukatpally, Telangana-500085, India.

M. Swathi Ramani*, M. Sunitha Reddy, K. Anie Vijetha, Formulation And Evaluation of Ezetimibe Nanoemulsion, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 9, 3577-3593 https://doi.org/10.5281/zenodo.17231103

More related articles
Designing, In Silico Screening and Molecular Docki...
Sagar Magar, Amol Dighe, Manisha Sonawane, Nilima Wani, Pradnya B...
Alternative Natural Treatment of Psoriasis...
Mayuri Raut, Shivprasad Deokar , Dr. Kawade Rajendra M., ...
In Silico Molecular Modeling Studies on Novel Imidazole Derivatives and Their Po...
Soumallya Chakraborty, Ankita Biswas, Somenath Bhattacharya, ...
Bioactive Compounds, Pharmacological study Health Benefits: A Review of Four Tra...
Deeksha sharma , Dr. Dev Prakash Dahiya, Anchal Sankhyan, Palak kumari, Manjula verma, ...
Revolutionizing Insulin Delivery: Emerging Trends and Technology ...
Unnati Patel, Dhanvi Patel, Mona A. Gupta, Dr. Nisha Patel, Sandhya Bodhe, ...
Related Articles
Solubility Enchantment Of Poorly Soluble Drug...
Kale kajal Santosh , Shinde S. B., ...
Toxicity and Adverse Effects of Herbal Ingredients in Cosmetic Products: A Compr...
Sayali N.Gade , Ajay K. Shirsat, Geetanjali G.Tambe, Dr.Sagar S.Muley, ...
In Situ Gel: A Novel Approach for Periodontitis Management...
Darshad Rane, Rashmi Mahabal, Namita Bhosale, Vijay Jagtap, ...
Improvement And Evaluation of Polyherbal Soap Incorporating Potato, Rice and Bat...
Vivek Pete, Pratiksha Ghatol, Samiksha Ambulkar, Yashashri Tarale, ...
Designing, In Silico Screening and Molecular Docking Studies of Some Novel 5-(4-...
Sagar Magar, Amol Dighe, Manisha Sonawane, Nilima Wani, Pradnya Bawake, Shainesh Bhosale, ...
More related articles
Designing, In Silico Screening and Molecular Docking Studies of Some Novel 5-(4-...
Sagar Magar, Amol Dighe, Manisha Sonawane, Nilima Wani, Pradnya Bawake, Shainesh Bhosale, ...
Alternative Natural Treatment of Psoriasis...
Mayuri Raut, Shivprasad Deokar , Dr. Kawade Rajendra M., ...
Designing, In Silico Screening and Molecular Docking Studies of Some Novel 5-(4-...
Sagar Magar, Amol Dighe, Manisha Sonawane, Nilima Wani, Pradnya Bawake, Shainesh Bhosale, ...
Alternative Natural Treatment of Psoriasis...
Mayuri Raut, Shivprasad Deokar , Dr. Kawade Rajendra M., ...